Steven Cohen Nurix Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.77 - $15.66 $73,815 - $148,770	9,500 New	9,500 $139,000
Q3 2023 Nov 14, 2023	BUY	$7.86 - $10.08 $8,701 - $11,158	1,107 Added 15814.29%	1,114 $8,000
Q2 2023 Aug 14, 2023	SELL	$8.7 - $13.28 $83,467 - $127,408	-9,594 Reduced 99.93%	7 $0
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $82,184 - $127,309	9,601 New	9,601 $85,000
Q2 2022 Aug 15, 2022	SELL	$7.88 - $14.82 $550,418 - $1.04 Million	-69,850 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$12.94 - $29.65 $863,098 - $1.98 Million	-66,700 Reduced 48.85%	69,850 $979,000
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $3.61 Million - $4.71 Million	136,550 New	136,550 $3.95 Million

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.